Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
07/26/07	SEK 0.8990	+9.23%	25,44,746
04/26/04	SEK 0.8230	-3.18%	9,39,919
03/26/03	SEK 0.8500	-0.35%	6,66,382
02/26/02	SEK 0.8530	+5.57%	14,11,147
01/26/01	SEK 0.8080	+1.00%	7,07,328

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 07/09/2026 pm IST			5-day change	1st Jan Change
0.8990 ^SEK	+9.23%		+12.38%	+8.44%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	18Cr 1.9Cr 1.63Cr 1.54Cr 1.4Cr 2.62Cr 179.65Cr 2.63Cr 7.04Cr 92Cr 7.13Cr 6.98Cr 293.04Cr	P/E 2026 *	-3.05x	P/E 2027 *	-2.17x
Enterprise Value	17Cr 1.73Cr 1.49Cr 1.4Cr 1.28Cr 2.39Cr 163.87Cr 2.4Cr 6.42Cr 84Cr 6.51Cr 6.36Cr 267.3Cr	EV / Sales 2026 *	5.3x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
08/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	+9.23%
1 week	+12.38%
Current month	+12.38%
1 month	-15.51%
3 months	+95.43%
6 months	+58.00%
Current year	+8.44%

1 week	0.77	0.95
1 month	0.75	1.08
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+9.23%	+12.38%	-34.38%	-71.73%	1.74Cr
LONZA GROUP AG	-1.16%	-2.77%	-1.68%	+13.85%	4.89TCr
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	4.5TCr
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	4.41TCr
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	4.07TCr
CELLTRION, INC.	-0.96%	-2.31%	+15.75%	+45.41%	3.35TCr
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	1.78TCr
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	1.65TCr
EUROFINS SCIENTIFIC SE	-1.54%	-1.05%	+12.16%	+29.80%	1.47TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	1.38TCr
Average	+0.06%	+0.23%	+61.69%	+89.60%	2.75TCr
Weighted average by Cap.	-0.95%	+0.05%	+89.18%	+128.57%

	2026 *	2027 *
Net sales	3.14Cr 32.69L 28.11L 26.44L 24.14L 45.14L 31Cr 45.29L 1.21Cr 16Cr 1.23Cr 1.2Cr 50Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.39Cr -6L -17.2L -2.25Cr -17.43L -17.04L -7.16Cr	-7.7Cr -80.29L -69.05L -64.94L -59.28L -1.11Cr -76Cr -1.11Cr -2.98Cr -39Cr -3.02Cr -2.95Cr -123.86Cr
Net Debt	-1.6Cr -16.68L -14.35L -13.49L -12.32L -23.04L -16Cr -23.11L -61.85L -8.08Cr -62.65L -61.28L -26Cr	-1.9Cr -19.81L -17.04L -16.02L -14.63L -27.36L -19Cr -27.45L -73.44L -9.59Cr -74.4L -72.77L -31Cr